Join
Live feed
·
PRReleasevia Quantisnow
Addex Therapeutics Ltd logo

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

ByQuantisnow·Wall Street's wire, on your screen.
ADXN· Addex Therapeutics Ltd
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADXN (Addex Therapeutics Ltd) and more on Quantisnow.